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Abstract
Backgound:  Angiomotin is a newly discovered molecule that regulates the migration and tubule
formation of endothelial cells. It therefore has been implicated in the control of angiogenesis under
physiological and pathological conditions. This study examined the expression of angiomotin and its
analogues, angiomotin-like 1 (L1) and -like 2 (L2) in breast tumour tissues, and analysed their correlation
with angiogenesis and clinical outcomes.
Methods: Human breast tissues (normal n = 32 and tumours n = 120) were used. The levels of expression
of angiomotin, L1 and L2 were determined using reverse transcription PCR. Microvessels were stained
using antibodies against PECAM, von Willebrand factor (factor 8, or vWF) and VE-cadherin. The transcript
levels of angiomotin and its analogues were assessed against the clinical and pathological background,
including long term survival (120 months).
Results: Breast cancer tissues expressed significantly higher levels of angiomotin transcript, compared
with normal mammary tissues (33.1 ± 11 in normal versus 86.5 ± 13.7 in tumour tissues, p = 0.003). Both
L1 and L2 were seen at marginally higher levels in tumour than normal tissues but the difference was not
statistically significant. Levels of angiomotin were at significantly higher levels in grade 2 and grade 3
tumours compared with grade 1 (p < 0.01 and p = 0.05 respectively). The levels of angiomotin in tumours
from patients who had metastatic disease were also significantly higher than those patients who remained
disease free (p = 0.03). Multivariate analysis indicated that angiomotin transcript was an independent
prognostic factor (p = 0.031). No significant correlations were seen between angiomotin-L1 and L2 with
the clinical outcome. Furthermore, high levels of angiomotin transcript were associated with shorter
overall survival (p < 0.05). There was a high degree of correlation between levels of vW factor and that
of angiomotin (p < 0.05), but not angiomotin-L1 and angiomotin-L2.
Conclusion: Angiomotin, a putative endothelial motility factor, is highly expressed in human breast
tumour tissues and linked to angiogenesis. It links to the aggressive nature of breast tumours and the long
term survival of the patients. These data point angiomotin as being a potential therapeutic target.
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Background
Angiogenesis is essential in the development and vascular
spread of cancer, by providing nutrients, oxygen, and pas-
sages for the departing cancer cells [1-3]. The angiogenic
process is regulated by a carefully maintained balance
between angiogenic factors and angiogenic inhibitors
(angiogenic factors). In cancer, the pro-angiogenic factors
frequently gain the 'upper hand', which stimulate vascular
endothelial cells to growth, migrate and forming new vas-
cular/capillary tubules. Most angiogenic factors are
growth factors that increase the proliferation of vascular
endothelial cells. Some factors, however, are strongly
involved in the migration and morphogenesis of endothe-
lial cells, such as hepatocyte growth factor. These factors
are mainly produced by stromal cells and act via a para-
crine pathway. Angiogenic factors, their receptors or mol-
ecules specific to vascular endothelial cells have been used
to assess angiogenesis. Notable ones include von Wille-
brand factor (factor-8 or vWF), PE-CAM, VE-Cadherin,
VEGF-receptors [4-6].
Angiomotin (AF286598) is a molecule recently identified
from its ability to bind to angiostatin using a yeast two
hybrid screen [7]. Angiomotin exerts a strong effect in
inducing the migration and tubule formation from
endothelial cells and promotes angiogenesis. The effect
appears to be via its interaction with and subsequent inhi-
bition of angiostatin, an angiogenesis inhibitor.  How-
ever, other mechanism(s) may also operate, including
possible interaction with integrins. Angiostatin is known
to inhibit angiogenesis and metastasis in solid tumours
[8]. Angiomotin belongs to a new protein family with
which its members share sequence and structural similar-
ities. Two other known members in the family include
angiomotin-like-1 and angiomotin-like-2 proteins [9].
Angiomotin-like-1 is also known as junction-enriched
and -associated protein (JEAP) that is highly located at
tight junctions and co-localised with JEAP [10]. Angiom-
otin-like-2 has, however, no known functions identified.
The potential pro-motility function of angiomotin has
suggested an important role of the molecule in angiogen-
esis. Indeed, it has been shown that transfection of micro-
capillary endothelial cells with angiomotin expression
vector increases the migration and tubule forming of the
cells [7]. Angiomotin deficient mice died in their early
days due to a migration defect during their development,
further indicating the potential role of angiomotin in cell
motility [11]. The important biological role of angiomo-
tin and its analogues indicates that it may play an impor-
tant role in angiogenesis in tumours. Indeed, angiomotin
has been found to be expressed highly in vessels of Kapo-
sis sarcoma, and weakly in vessels from normal tissues in
an early study [7]. However, the expression, distribution
pattern and the clinical implications of angiomotin in
other tumour types are yet to be explored.
Breast cancer is the leading female cancer in U.S. and U.K.
The metastatic spread of the tumour is the primary cause
of death of the patients. In the past decade, angiogenesis
has been shown to be an important biological marker in
predicting prognosis and clinical outcome of patients
with breast cancer. Traditionally, angiogenesis has been
assessed using markers including von Willebrand factor
(vWF), VE-cadherin (also known as cadherin-5) and PE-
CAM (CD31), and has been found to be increased in
tumour tissues compared with normal tissues [12-15].
Micro-vessel density (MVD) has been used as a mean to
calculate angiogenesis in these studies and has been
shown to be associated with the progress and metastasis
of breast cancer [16,17]. A number of the angiogenic fac-
tors, such as VEGF has also shown to be linked to progno-
sis in patients with breast cancer.
We examined the expression of angiomotin and its ana-
logue molecules angiomotin-like-1 and like-2 in a cohort
of breast tumours against the clinical information. Here,
we report for the first time the aberrant expression of angi-
omotin in breast tumours, its correlation with angiogen-
esis and association with metastatic disease in patients
with breast cancer.
Table 1: Clinical and pathological information of the study cohort. Shown are number of samples in each group
Node status Node negative Node positive
n= 65 55
Grade Grade 1 Grade 2 Grade 3
n= 23 41 56
Histology Ductal Lobular Medullary Tubular Mucinous Others
n= 94 14 2 2 4 4
TNM staging TNM 1 TNM 2 TNM 3 TNM 4
n= 69 40 7 4
Clinical outcome Disease free With Metastasis With local recur. Died of breast Cancer Died of unrelated diseases
n= 81 7 5 20 7BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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Methods
Materials
RNA extraction kit and RT kit were obtained from AbGene
Ltd, Surrey, England, UK. PCR primers were designed
using Beacon Designer (Palo Alto, California, USA) and
synthesised by Invitrogen Ltd (Pasley, Scotland, UK).
Molecular biology grade agarose and DNA ladder were
from Invitrogen (Pasley, Scotland, UK. Master mix for
routine PCR and quantitative PCR was from AbGene (Sur-
rey, England, UK). Rabbit anti-human VE-cadherin and
anti-factor-8 (von Willebrand Factor), goat anti-rabbit
and an universal staining kit were from Santa Cruz Bio-
technology Ltd (Santa Cruz, CA, USA), and Vector Labo-
ratories (Nottingham, England, UK), respectively.
Sample collection
Breast cancer tissues (n = 120) and normal background
tissues (n = 32) were collected immediately after surgery
and stored in the deep freezer until use. Patients were rou-
tinely followed clinically after surgery. The median fol-
low-up period was 120 months (June 2004). The presence
of tumour cells in the collected tissues was verified by a
consultant pathologist, who examined H&E stained fro-
zen sections. Details of histology were obtained from
Pathology reports and re-verified by a consultant patholo-
gist (ADJ) (table 1). Patients were routinely followed up
on a regular basis and details stored in a database.
Tissue processing, RNA extraction and cDNA synthesis
Frozen sections of tissues were cut at a thickness of 5–10
µm and were kept for immunohistochemistry and routine
histology. Additional 15–20 sections were mixed and
homogenised using a hand-held homogeniser, in ice cold
RNA extraction solution. The concentration of RNA was
determined using a UV spectrophotometer. Reverse tran-
scription was carried using a RT kit with an anchored
oligo-dt primer supplied by AbGene, using 1 µg total RNA
in 96-well plate. The quality of cDNA was verified using β-
actin primers.
Quantitative analysis of the transcripts of angiomotin, 
angiomotin-related molecule, and endothelial markers
The level of angiomotin, angiomotin-like-1 and angiom-
otin-like-2, PECAM-1, VE-cadherin and factor-8 tran-
scripts from the above-prepared cDNA was determined
using a real-time quantitative PCR, based on the Amplif-
luor™ technology, modified from a method previous
reported [17,18]. Briefly, pairs of PCR primers were
designed using the Beacon Designer software (version 2,
California, USA). To one of the primers, an additional
sequence, known as the Z sequence (5'actgaacctgaccgt-
aca'3) which is complementary to the universal Z probe
(Intergen Inc., Oxford, England, UK), was added.
Sequences of the respective primers were: Angiomotin
(5'atacggtgatggagaaacag'3 and 5'ctgaagaactgcgactgtg'3),
Angiomotin-like-1 (5'catgagagcctgaccaga'3, and 5'cctcatt-
tcactgtccatct'3), angiomotin-like-2 (5'caccatcaccaccaccat'3
and 5'agaaacagcagcagcagtag'3), PECAM-1 (CD31)(5'ccat-
catgggaggtgatg'3 and 5' actgaacctgaccgtacatgctgagacct-
gcttttc'3), VE-cadherin (5' gggagaccacgcctctgtc'3 and 5'
actgaacctgaccgtagaggaggccctgggcatctc'3), vWF (5' ggaga-
gatgggacactaaca'3 and 5' actgaacctgaccgtacagtcatatggac-
gactgaggt'3)and  β-actin: 5'atgatatcgccgcgctcg'3 and
5'cgctcgtgtaggatcttca'3 A Taqman detection kit for β-actin
was purchased from Perkin-Elmer. The reaction was car-
ried out using the following: Hot-start Q-master mix
(Abgene), 10 pmol of specific forward primer, 1 pmol
reverse primer which has the Z sequence, 10 pmol of
FAM-tagged probe (Intergen Inc., Oxford, England, UK),
and cDNA from approximate 50 ng RNA. The reaction
was carried out using IcyclerIQ™ (Bio-Rad) which is
equipped with an optic unit that allows real time detec-
tion of 96 reactions, using the following condition: 94°C
for 12 minutes, 50 cycles of 94°C for 15 seconds, 55°C for
40 seconds and 72°C for 20 seconds. The levels of the
transcripts were generated from a standard that was simul-
taneously amplified with the samples. Cytokeratin-19
(CK19) was used for comparison of cellularity during the
analysis and primers for CK19 were 5'-caggtccgaggttact-
gac-3' and 5'-actgaacctgaccgtacacactttctgccagtgtgtcttc-3'
respectively [19,20]. The levels of the angiomotin and the
angiomotin like transcripts are shown here as the number
of the respective copies and the ratio of angiomotin (or its
like proteins) vs cytokeratin 19 (CK19).
Assessment of micro-vessel density (MVD) using anti-von 
Willebrand Factor (vWF) and VE-cadherin
The assessment of MVD was as previously reported
[21,22]. Frozen sections of breast tumour and background
tissue were cut at a thickness of 6 µm using a cryostat. The
sections were mounted on super frost plus microscope
slides, air dried and then fixed in a mixture of 50% Ace-
tone and 50% methanol. The sections were then placed in
"Optimax" wash buffer for 5–10 minutes to rehydrate.
Sections were incubated for 20 mins in a 0.6% BSA block-
ing solution and probed with the primary antibody (1:50
dilution) for 2 hours at room temperature. Following
extensive washings, sections were incubated for 30 mins
in the secondary biotinylated antibody (Multilink Swine
anti- goat/mouse/rabbit immunoglobulin, Dako Inc.).
Following washings, Avidin Biotin Complex (Vector Lab-
oratories) was then applied to the sections followed by
extensive washings. Diamino benzidine chromogen (Vec-
tor Labs) was then added to the sections which were incu-
bated in the dark for 5 mins. Sections were then counter
stained in Gill's Haematoxylin and dehydrated in ascend-
ing grades of methanol before clearing in xylene and
mounting under a cover slip. Microvessels were counted
using X20 objectives by 3 independent researchers, as we
have recently reported [21].BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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Expression of angiomotin and angiomotin like transcript in normal and tumour tissues using conventional RT-PCR (A) and  quantitative real-time PCR (B) Figure 1
Expression of angiomotin and angiomotin like transcript in normal and tumour tissues using conventional RT-PCR (A) and 
quantitative real-time PCR (B). A: paired normal (N) and tumour (T) tissues from selected patients. B: levels of the respective 
transcript and the transcript:CK19 ratio (inserts) from all the samples (normal n = 32 and tumour n = 120). * p < 0.05 vs 
tumours.BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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Statistical analysis was carried out using Mann-Whitney U
test and the Kruskal-Wallis test. Survival analysis was car-
ried out using the Kaplan-Meier's and Cox Proportional
tests with SPSS12 package.
Results
Expression of angiomotins in mammary tissues
The presence of angiomotin and the angiomotin-like tran-
scripts were detected in both normal and tumour mam-
mary tissues (figure 1A). In these selective paired samples,
it was seen that most tumour samples had a stronger angi-
omotin signal, however, signals for angiomotin-like-1
and -like-2 were not different between normal and
tumour tissues.
A quantitative analysis of the molecules indicated that
there was a significantly higher level of angiomotin in
breast tumour tissues, than in normal tissues (figure 1B-
a). The same trend was reflected when the transcripts were
normalised by CK19, as measure of controlling the cellu-
larity (figure 1B-a insert). Angiomotin like-1 and like-2
transcript were also high in tumour tissues compared with
normal tissues (figure 1B-b and 1B-c, respectively), how-
ever, the difference was not statistically significant. More-
over, after being normalised by CK19, as shown in figure
1B inserts, tumour tissues exhibited a lower ratio, com-
pared with normal tissue, although this was not statisti-
cally significant. No significant difference between
normal and tumour was seen for the angiomotin-like-
2:CK19 ratio.
Angiomotin and histological type and tumour grade
Grade-2 and grade-3 tumours had significantly higher lev-
els of angiomotin transcript than grade 1 tumours (p =
Levels of expression of angiomotins and their relationship with grade (Top panel, A-C) and histological types (bottom panel, D- F) Figure 2
Levels of expression of angiomotins and their relationship with grade (Top panel, A-C) and histological types (bottom panel, D-
F). A and D: angiomotin, B and E: angiomotin-like-1, C and F: angiomotin-like-2. ** p = 0.01, * p = 0.049, vs grade 1 tumours. 
Inserts: respective angiogemotin transcript:CK19 transcript ratio.BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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Angiomotins in nodal status (top panel, A-C) and predicted prognosis (bottom panel, E-F) Figure 3
Angiomotins in nodal status (top panel, A-C) and predicted prognosis (bottom panel, E-F). A and D: angiomotin, B and E: angi-
omotin-like-1, C and F: angiomotin-like-2. A, B AND C : difference between node negative and node positive tumours. * p < 
0.01 vs node negative tumours. D, E &F: angiomotins and predicted clinical outcome based on Nottingham Prognostic Index 
(NPI = (0.2 × size) + grade + Nodal status). NPI<3.4, 3.4–5.4 and >5.4 represented good (15 year survival rate 80%) (NPI1), 
moderate (15 year survival 42%) (NPI2) and poor prognosis (15 year survival 15%). Inserts: respective angiomotin tran-
script:CK19 transcript ratio.BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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0.01 Grade 1 vs grade 2, p < 0.05 grade 1 vs grade 3) (fig-
ure 2A). The angiomotin:CK19 ratio was also significantly
higher in grade 2 and grade 3 tumours compared with
grade 1 tumours (figure 2A insert). No significant differ-
ence between different grades was seen with angiomotin-
Like-1 or its ratio to CK19 (figure 2B and insert). A mar-
ginally high level of angiomotin-like-2 was seen in grade
3 tumours, however neither the transcript nor the tran-
script:CK19 reached a statistical difference (figure 2C and
insert).
Ductal tumours had higher levels of angiomotin (91.4 ±
13.7) than lobular tumours (48.1 ± 16, p = 0.026) (figure
2D). A similar trend was seen with angiomotin-like-1
(298.8 ± 51.4 for ductal and 78.1 ± 25.7 for lobular, p =
0.045). Levels of angiomotin like-2 transcript were mar-
ginally higher in ductal tumours (139 ± 92), compared
with lobular tumours (29.2 ± 7.3) p = 0.24) (figure 2E and
2F).
Angiomotin is associated with nodal involvement and 
predicted clinical outcome
There was a significantly higher level of angiomotin and
angiomotin:CK19 ratio in tumour with positive axillary
nodes (p = 0.0018) (figure 3A and insert). Although there
was a trend of higher levels of angiomotin-like-1 and -
like-2 in node positive tumours, this was not significant (p
= 0.08 and p = 0.6, respectively, figure 3B and 3C).
We have used Nottingham Prognostic Index (NPI) as an
indicator for predicted clinical outcome. As shown in fig-
ure 3D, although there was a trend of high level of angi-
omotin transcript in moderate and poor prognostic
tumours, statistical difference was only seen with angiom-
otin:CK19 ratio (figure 3D and its insert). No significant
difference was otherwise seen with angiomotin-like-1 and
angiomotin-like-2 (figure 3E and 3F).
Correlation of levels of angiomotin with angiogenesis and 
other angiogenic markers
We also quantified the levels of VE-cadherin, PECAM-1
and vWF as an indicator of degree of angiogenesis in
breast cancer, as we previously reported [21]. There was an
increased level of VE-cadherin in breast tumour tissues
(2.4 ± 0.64), compared with normal background tissues
(1.9 ± 0.61), p = 0.7. Similarly, a high level of PECAM1
(CD31) in tumour tissues (275.0 ± 73.7), compared with
normal background tissues (145.7 ± 30.0), p = 0.8. A
Spearman correlation test between PECAM1, VE-cadherin
and angiomotins revealed a significant correlation
between angiomotin transcript and VE-cadherin as well as
PECAM1 (r = 0.35 and r = 0.338, p < 0.05 respectively).
Angiomotins and clinical outcomes Figure 4
Angiomotins and clinical outcomes. Patients were assessed based on the outcome after 10 years from initial surgery, and were 
divided into those who remained disease free, with metastasis, with local recurrence and who died of breast cancer related 
causes. Inserts: respective angiomotin transcript:CK19 transcript ratio. * p = 0.03 vs disease free group.BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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Angiomotin transcript levels were also significantly corre-
lated with microvessel count (MVD) using anti-vWF (r =
0.400, p < 0.05). There was no significant correlation
between levels of these factors and angiomotin-like-1 and
angiomotin-like-2.
Implications of angiomotin with clinical outcome
Following a median 120 month followup, patients were
divided into the following groups: those who remained
disease free, who developed metastasis or local recur-
rence, and those who died of breast cancer related disease
(excluding non-cancer related deaths). Angiomotin was
seen at significantly higher levels in patients who devel-
oped metastatic disease compared with those who
remained disease free (p = 0.03) (figure 4 left). Although
tumours from patients with local recurrence and who died
of breast cancer also had a higher level of angiomotin, the
difference was nonetheless not significant. Levels of both
angiomotin like-1 and like-2 transcripts were lower in
patients who had a poor clinical outcome, although the
difference was not statistically significant (figure 4 middle
and right).
We have divided patients into two groups, those with high
levels of angiomotin and those with low levels of angiom-
otin, by using the prognostic index, NPI, as a general ref-
erence. Where a tumour had angiomotin level higher than
the mean level of NPI-2 group (NPI 3.4–5.4, with moder-
ate prognosis), it was assigned as high. Kaplan-Meier sur-
vival analysis has shown that patients bearing tumours
with high levels of angiomotin were associated with a
shorter overall survival (119.9 (105.2–134.7 95% CI)
months vs 136.5 (124.5–148.4, 95%CI) months for
patients with low angiomotin transcript, p < 0.05) (figure
The correlation between Angiomotin (A and D), angiomotin-like-1 (B and E) and angiomotin-like-2 (C and F) and Overall Sur- vival (A-C) and disease free survival (D-F), using Kaplan-Meier survival analysis Figure 5
The correlation between Angiomotin (A and D), angiomotin-like-1 (B and E) and angiomotin-like-2 (C and F) and Overall Sur-
vival (A-C) and disease free survival (D-F), using Kaplan-Meier survival analysis. Levels of angiomotin transcript were associated 
with the overall survival (A).BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
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5A). No significant correlation was seen between overall
survival and Angiomotin-L1 and L2 (figure 5B and 5C).
Similarly, patients bearing tumours with high levels of
angiomotin were associated with a shorter disease free
survival (108.6 (92.3–125.0 95% CI) months vs 134.3
(122.0–146.7, 95%CI) months for patients with low angi-
omotin transcript, however, the difference was not statis-
tically significant, p = 0.0634) (figure 5D). No significant
correlation was seen between disease free survival and
Angiomotin-L1 and L2 (figures 5E and 5F). Using multi-
variate analysis of the following factors, nodal status,
tumour grade, angiomotin, angiomotin-like-1 and angi-
omotin-like-2, we have found that nodal status (p =
0.0185) and angiomotin transcript (p = 0.031) were inde-
pendent survival factors.
Furthermore, we have found that angiomotin-L1 was
expressed at a significantly lower level in ER positive
tumours compared with ER negative tumours (table 2).
No significant difference was seen with angiomotin, angi-
omotin-L2 and ER status.
Discussion
Angiogenesis is the essential process in the development
and spread of breast cancer, by providing blood supply to
tumours and escape route for tumour cells to other part of
the body. Here we report that angiomotin, a protein that
regulate the motility and morphology of endothelial cells
is highly expressed in human breast tissues and that its
levels are associated with other angiogenic markers and
with the clinical outcome in patients with breast cancer.
Angiomotin is a motility regulator of vascular endothelial
cells and may be a molecule that links to breast cancer
growth and spread by way of stimulating angiogenesis.
The current study provides lines of evidence to support
this possibility. First, angiomotin is highly expressed in
aggressive tumours (grade 2 and 3 and tumours with
nodal involvement) than in less aggressive tumours. Sec-
ond, levels of angiomotin are correlated with levels of
angiogenic markers. Third, significantly higher levels of
angiomotin transcript are seen in patients with metastatic
disease. These data, together with the report that angiom-
otin directly enhances angiogenesis in vitro and in vivo,
suggest that angiomotin is linked to the angiogenic and
aggressive nature of breast cancer. However, it would
require additional work to verify if angiomotin and angi-
omotin like proteins can be reliable surrogate markers for
angiogenesis.
Although angiomotin-like-1 and -like-2 proteins are also
expressed at higher levels in breast tumour tissues, the dif-
ference is not significant. There are no consistent patterns
to suggest these two analogues of angiomotin are also
linked to the aggressiveness of breast tumours, although
both of the angiomotin related proteins are expressed in
endothelial cells [23]. In fact, the levels of both analogues
decrease in tumours that are associated with metastasis
and mortality, which is in clear contrast with that of angi-
omotin. Currently there is no clear explanation to the
seemingly different role between angiomotin and angi-
omotin like proteins. However, angiomotin-like-1 protein
is known to be a tight junction related molecule and is
highly located in tight junctions [10]. Recent years have
seen significant advances in the understanding of the biol-
ogy and role of tight junction in endothelium as defence
mechanism in preventing blood borne cancer cells to
escape. Tight junctions in endothelial cells may act as a
'sealing' structure to separate the blood circulation from
tissue space [24]. Endothelial tight junctions act as a nat-
ural barrier for the vascular spread of cancer cell, by keep-
ing the circulating cancer cells 'at bay-in the circulation'.
In epithelial cells, as well as being a permeability barrier,
tight junctions act as a strong cell adhesion mechanism
and have a potential tumour suppressor role [25]. It has
been reported that loss of certain tight junctional mole-
cules, such as ZO-1, ZO-2, and occludin are frequently
seen in clinical tumours and the loss of these TJ molecules
is associated with the aggressiveness of tumours [26-29].
Thus, it is anticipated that angiomotin-like-1 protein, may
act very different from angiomotin, potentially through
their participation in tight junctions. Clearly, this is a fer-
tile area to investigate in the future. The study has also
indicated that ER negative tumours had a significantly
higher level of angiomotin-L1 transcripts than in ER posi-
tive tumours. Although angiomotin-L2 transcripts were
higher in ER negative tumours than in ER positive
tumours, the difference was not statistically significant. In
contrast, no difference was seen with angiomotin tran-
script between the two groups. This presents an interesting
link between ER status and the angiomotin-L1 transcript.
It has been established that ER negative tumours are asso-
ciated with a poorer prognosis than ER positive tumours.
It is possible that high levels of angiomotin-L1 in the ER
Table 2: Levels of angiomotin transcript and their relationship with ER status. Shown are number of the respective transcript.
ER(-) ER(+) P value
Angiomotin 87.2 ± 16.8 101.7 ± 29.7 P = 0.67
Angiomotin-L1 383.7 ± 86.0 167.6 ± 39.1 P = 0.024
Angiomotin-L2 174.0 ± 120 31.7 ± 8.6 P = 0.24BMC Cancer 2006, 6:16 http://www.biomedcentral.com/1471-2407/6/16
Page 10 of 10
(page number not for citation purposes)
negative tumours contribute to this clinical link. Another
potential link is that an intrinsic relationship between the
expression of angiomotin-L1 and oestrogen in breast can-
cer may exist. Clearly, more experimental work is required
here.
Conclusion
Although it is at early stage in the investigation of angiom-
otin and its family into breast cancer, the current study
and recent reports have clearly shown the important role
of angiomotin in angiogenesis and in the aggressive
nature of breast tumours. These data suggest that angiom-
otin is not only a highly useful prognostic indicator in
breast cancer, it may also be a valid therapeutic target in
cancer.
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